Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004584 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004584 is a Phase 2 study that has completed, run by Bristol-Myers Squibb.
The verdict
NCT00004584, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to look at the safety and effectiveness of an experimental protease inhibitor (a type of anti-HIV drug) called BMS-232632. Doctors will compare an anti-HIV drug combination that includes BMS-232632 to a drug combination that includes ritonavir.
Interventions
- DRUG Ritonavir
- DRUG Atazanavir
- DRUG Saquinavir
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Est. Completion | 2002-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004584
The ClinicalTrials.gov registry entry for NCT00004584 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ritonavir is the first listed.
NCT00004584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004584 about?
NCT00004584 is a clinical study titled "Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment". The purpose of this study is to look at the safety and effectiveness of an experimental protease inhibitor (a type of anti-HIV drug) called BMS-232632. Doctors will compare an anti-HIV drug combination that includes BMS-232632 to a drug combination that includes ritonavir.
What is the current status of trial NCT00004584?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-12. Estimated completion is 2002-01.
What interventions are being tested in trial NCT00004584?
The interventions under investigation include: Ritonavir (DRUG), Atazanavir (DRUG), Saquinavir (DRUG).
Who is sponsoring clinical trial NCT00004584?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.